Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.42 |
| ▸ | KIT | P10721 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009662 | 0.91 | CYP1A2 (0.42) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL10010643 | 0.89 | MAPK1 (0.40) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL1506374 | 0.88 | KIT (0.41) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL1506086 | 0.88 | CYP1A2 (0.42) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL1506130 | 0.86 | RECQL (0.40) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL1506162 | 0.85 | CYP1A2 (0.40) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL1506199 | 0.85 | CYP1A2 (0.41) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL1506157 | 0.84 | P2RX7 (0.41) | P2RX7MAPK1 | |
| SCHEMBL1506259 | 0.83 | ADORA3 (0.38) | BRAFKITCYP1A2ADORA3ADORA2A | |
| SCHEMBL1506317 | 0.83 | BRAF (0.38) | BRAFKITCYP1A2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791144-B2 | Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2491024-B1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | BRAF 3496/4885KIT 1930/4885CYP1A2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.